Immunotherapycervical cancerlisteria monocytogenes vaccineHuman papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live...
在Advaxis公司近期向FDA提交的一份安全性报告中,包括了1例2013年的一项研究者主导的研究中接受过ADXS11-001的宫颈癌患者,该患者于近期死亡。因此FDA作出了暂停的决定。 ADXS11-001是一种用于治疗宫颈癌和头颈癌的疫苗,之前曾被称为ADXS-HPV。其作用原理是将李斯特菌进行大幅度减毒,并进行基因重组,使其分泌重组李...
在Advaxis公司近期向FDA提交的一份安全性报告中,包括了1例2013年的一项研究者主导的研究中接受过ADXS11-001的宫颈癌患者,该患者于近期死亡。因此FDA作出了暂停的决定。 ADXS11-001是一种用于治疗宫颈癌和头颈癌的疫苗,之前曾被称为ADXS-HPV.其作用原理是将李斯特菌进行大幅度减毒,并进行基因重组,使其分泌重组李斯...
ADXS11-001 can be safely administered to patients with advanced cancer alone and in combination with chemotherapy. ADXS11-001 is well tolerated and presents a predictable and manageable safety profile. The addition of cisplatin to ADXS11-001 in this study did not significantly improve tumor ...
ADXS11-001 immunotherapy targeting HPV-E7: Preliminary safety data from two phase 2 studies in women with CIN 2/3 and with recurrent/refractory cervical cancerAqua, K ABasu, PPetit, R G
A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 2018;28:764-72.Basu, P.; Mehta, A.; Jain, M.; Gupta, S.; Nagarkar, R.V.; John, S.; Petit, R. A ...
High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancerNo Abstract available for this article.doi:10.1186/2051-1426-3-S2-P151Ghamande, SharadMauro, DavidPrice, Cheryl...
ADXS11-001 immunotherapy targeting HPV- E7: final results from a phase 2 study in Indian women with recurrent cer- vical cancer. J Clin Oncol. 2014;32 abstract 5610.Petit RG, Mehta A, Jain M, Gupta S, Nagarkar R, Kumar V, Pre- mkumar S, Neve R, John S, Basu P. ADXS11-001 ...
Fifteen Percent Of ADXS11-001 Treated Cervix Cancer Patients Still Alive Three Years After Initial DosingAdvaxis, Incorporated
Cohen EE, Moore KN, Slomovitz BM, Chung CH, Anderson ML, Morris SR, et al. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. J Immunother Cancer....